Please check your internet connection and try again.
# MegaCV
## Overview
MegaCV is a combination medication containing a statin and ezetimibe, used to lower cholesterol levels.
## Primary Indications
* Primary hyperlipidemia (heterozygous familial and non-familial)
* Homozygous familial hypercholesterolemia (HoFH)
## Adult Dosing
* **Primary hyperlipidemia:** 10/10 mg to 10/80 mg once daily.
* **HoFH:** 10/80 mg once daily.
The usual starting dose is 10/10 mg once daily. Doses should be individualized based on patient response and goals.
## Pediatric Dosing
The safety and efficacy of MegaCV in pediatric patients have not been established.
## Dose Adjustments
* **Renal impairment:** No dose adjustment required for mild to moderate renal impairment. Use with caution in severe renal impairment.
* **Hepatic impairment:** Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.
## Contraindications
* Active liver disease or unexplained persistent elevations of serum transaminases.
* Hypersensitivity to any component of the drug.
* Concomitant use with cyclosporine (unless used for organ transplant).
## Adverse Effects
* **Common:** Diarrhea, upper respiratory tract infection, arthralgia, fatigue, cough, muscle pain, nausea, back pain, headache.
* **Serious:** Myopathy and rhabdomyolysis (especially at higher doses or when combined with other medications that can cause myopathy), hepatotoxicity, pancreatitis, angioedema, Stevens-Johnson syndrome, peripheral neuropathy.
## Key Drug Interactions
* **Cyclosporine:** Increased systemic exposure to simvastatin and ezetimibe.
* **Fibrates and Gemfibrozil:** Increased risk of myopathy.
* **Niacin:** Increased risk of myopathy.
* **Colchicine:** Increased risk of myopathy.
* **CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, protease inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone, cobicistat-containing products):** Increased risk of myopathy.
* **Certain calcium channel blockers (e.g., diltiazem, verapamil):** Increased simvastatin exposure.
* **Digoxin:** Increased digoxin levels may occur.
## Monitoring
* Lipid profiles (total cholesterol, LDL-C, HDL-C, triglycerides) at baseline and periodically thereafter.
* Liver function tests (ALT, AST) at baseline and as clinically indicated.
* Creatine kinase (CK) and urine myoglobin if myopathy is suspected.
## Clinical Pearls
* MegaCV can be taken with or without food.
* Higher doses of the simvastatin component (40 mg and 80 mg) are associated with an increased risk of myopathy.
* Monitor for signs and symptoms of myopathy, including muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.
* Consider risks and benefits of concomitant use with other medications known to cause myopathy.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and guidelines for complete details, including contraindications, warnings, precautions, drug interactions, and adverse reactions, before making any treatment decisions.
